Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Indonesia Energy Corporation Limited — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Indonesia Energy Corporation Limited trades at $2.83 (market cap $44.31M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 101.3× Indonesia Energy Corporation Limited's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| ACAD | INDO | |
|---|---|---|
Market Cap | $4.49B | $44.31M |
Sector | Health | Energy |
52-Week High | $28.06 | $6.74 |
52-Week Low | $20.06 | $2.49 |
Enterprise Value | $3.69B | $39.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
INDO trades at $2.79 with no recent price movement. The stock shows mixed technical signals with a bullish overall rating but bearish moving averages. Fundamentally, the company reported negative profitability metrics with a -253.4% net income margin on $2M revenue in 2025, though recent news highlights operational progress with new well drilling at the Kruh Block. Analyst consensus is unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of drilling operations to improve financial performance. Key opportunities include potential revenue growth from new wells, while risks center on continued negative cash flow and profitability challenges. The stock presents speculative potential for investors betting on operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
